Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095446
Status:
COMPLETED
Last Update Posted:
2017-01-04
First Post:
2004-11-04
Brief Title:
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
An Open-Label Multi Center Clinical Trial External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart NovoLog in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in the United States of America USA The aim of this trial is to assess control of blood sugar safety and patient acceptance of insulin aspart compared to insulin lispro both in insulin pumps in standard clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None